Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?

In the last 20 years there has been a huge increase in the number of novel drugs for cancer treatment. Most of them exploit their ability to target specific oncogenic mutations in the tumors (targeted therapies–TT), while others target the immune-checkpoint inhibitor molecules (ICI) or the epigeneti...

Descripción completa

Detalles Bibliográficos
Autores principales: Damele, Laura, Ottonello, Selene, Mingari, Maria Cristina, Pietra, Gabriella, Vitale, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226262/
https://www.ncbi.nlm.nih.gov/pubmed/32218226
http://dx.doi.org/10.3390/cancers12040774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226262/
https://www.ncbi.nlm.nih.gov/pubmed/32218226
http://dx.doi.org/10.3390/cancers12040774

Ejemplares similares